中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 5
May  2008

老年人慢性丙型肝炎的临床分析

  • Published Date: 2008-05-20
  • Objective To evaluate clinical features and treatment of chronic hepatitis C (CHC) in the aged patients.Methods Clinical data of 94 patients diagnosed with CHC were reviewed.Elderly patients (≥60 years) were compared in terms of clinical, biochemical, immunological features and treatment with younger patients (<60years) .Results Among the 94 patients.the initial diagnosis of CHC was made in 51 patients at an age≥60.The elder patients had similar clinical manifestations, except for higher liver cirrhosis ratio compared with younger patients (39.2% VS 16.3%, P<0.01) .The serum level of white blood cell and platelet count was lower in elderly patients compared with that of younger patients (P<0.01) , whereas there were no statistical differences in the serum HCV RNA levels, serum alanine aminotransferase, the serum total bilirubin and immunological findings between older and younger patients (P>0.05) .The ratio accommodate Peg-interferon alfa-2b plus ribavirin therapy lower in the elderly than in younger group (35.3% VS 81.4%, P<0.01) .among therapy Discontinuation or dose reduction was more frequent in older patients (P<0.05) .Conclusion Elderly patients have more complication compared with younger patients.They have lower tolerance with combination antiviral therapy.compared with younger patients.This suggests that we should diagnose and treat CHC early.

     

  • [1]WHO consulation organized in collaboration with the viral hepatitisprevention board.Global surveillance and control of hepatitis C[J].J Viral Hepat, 1999, 6∶35-47.
    [2]Manns MP, McHutchison JG, Gordon SC, et al.Peg-interferon al-fa-2b plus ribavirin compared to interferon alfa-2b plus ribavirinfor the treatment of chronic hepatitis C.A randomized trial[J].Lan-cet, 2001, 358 (9286) ∶958-965.
    [3]Fried MW, Shiffman ML, Reddy KR, et al.Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C infection[J].NEngl J Med, 2002, 347 (13) ∶975-982.
    [4] 中华医学会.丙型肝炎防治指南[J].中华内科杂志, 2004, 43∶551-555.
    [5]Shiratori Y, Imazeki F, Moriyama M, et al.Histological improve-ment of fibrosis in patient with hepatitis C who have sustained re-sponse to interferon therapy[J].Ann Intern Med, 2000, 132∶517-524.
    [6]Yoshida H, Shiratori Y, Moriyama M, et al.Interferon therapy re-duces the risk for hepatocellular carcinoma development:nature sur-veillance program of cirrhotic and noncirrhotic patients with chronichepatitis C in Japan[J].Ann Intern Med, 1999, 131∶174-181.
    [7]Imai Y, Kasahara A, Tanaka H, et al.Interferon therapy for agedpatients with chronic hepatitis C:improved survival in patients exhib-iting a biochemical response[J].J Gastroenterol, 2004, 39∶1069-1077.
    [8]Yoshida H, Arakawa Y, Sata M, et al.Interferon therapy prolongedlife expectancy among chronic hepatitis C patients[J].Gastroenterol-ogy, 2002, 123∶483-491.
    [9]McHutchison JG, Gordon SC, Schiff ER, et al.Interferon alfa-2balone or in combination with ribavirin as initial treatment for chronichepatitis C.Hepatitis Interventional Therapy Group[J].N Engl JMed, 1998, 339∶1485-1492.
    [10]Sulkowski MS, Wasserman R, Brooks L, et al.Changes in haemo-globin during interferon alpha-2b plus ribavirin combination therapyfor chronic hepatitis C virus infection[J].J Viral Hepat, 2004, 11∶243-250.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2073) PDF downloads(811) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return